205 related articles for article (PubMed ID: 28976408)
1. Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
Rojas JI; Patrucco L; Miguez J; Cristiano E
Clin Neuropharmacol; 2017; 40(6):251-254. PubMed ID: 28976408
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
Patrucco L; Cristiano E; Sánchez F; Miguez J; Rojas JI
Clin Neuropharmacol; 2019; 42(5):163-166. PubMed ID: 31348014
[TBL] [Abstract][Full Text] [Related]
3. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
4. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
9. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen P; Hartikainen JE
Mult Scler; 2016 Jul; 22(8):1080-5. PubMed ID: 26362903
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
Tichá V; Kodým R; Počíková Z; Kadlecová P
Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
[TBL] [Abstract][Full Text] [Related]
11. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
Zecca C; Roth S; Findling O; Perriard G; Bachmann V; Pless ML; Baumann A; Kamm CP; Lalive PH; Czaplinski A
Eur J Neurol; 2018 May; 25(5):762-767. PubMed ID: 29431876
[TBL] [Abstract][Full Text] [Related]
12. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2015 Jun; 15():93. PubMed ID: 26084334
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study.
Saida T; Itoyama Y; Kikuchi S; Hao Q; Kurosawa T; Ueda K; Auberson LZ; Tsumiyama I; Nagato K; Kira JI
BMC Neurol; 2017 Jan; 17(1):17. PubMed ID: 28129749
[TBL] [Abstract][Full Text] [Related]
16. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
17. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
19. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
Montgomery SM; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod in multiple sclerosis: profile of use in habitual practice.
Fernández Bargiela N; Mondelo García C; Giménez Arufe V; Vizoso Hermida JR; Martín Herranz I
Eur J Hosp Pharm; 2020 Nov; 27(6):346-349. PubMed ID: 33097618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
